[Risk factors for ventricular peritoneal shunt infection in pediatric patients from the hospital Carlos Van Buren]. / Factores de riesgo de infección de derivativa ventrículo peritoneal en pacientes pediátricos del Hospital Carlos Van Buren.

Hydrocephalus is a common problem in Neurosurgery and Neurology. The usual treatment is the installation of a Ventricular Peritoneal Shunt (VPS). Infection is the most frequent and serious complication. With the aim to identify risk factors associated with infection in the post surgery of VPS in pediatric patients from Carlos Van Buren Hospital a case control study between 1998-2008 was done. Cases were patients with VPS infection reported to the Department of Nosocomial Infections. Results in contingency tables were analyzed to determine Odds Ratio. 264 surgical procedures were studied in 207 patients with 53 infections reported in 26 patients. Significant risk factors were: history of prior ventriculitis, VPS dysfunction and prior external ventricular shunt, concurrent infections at the time of surgery and a neurosurgeon without the specialty of pediatric neurosurgery. We concluded that antibiotic prophylaxis was not an important factor in preventing infection and the neurosurgeon experience is relevant to the development of VPS infections.

Factores de riesgo de infección de derivativa ventrículo peritoneal en pacientes pediátricos del Hospital Carlos Van Buren / Risk factors for ventricular peritoneal shunt infection in pediatric patients from the hospital Carlos Van Buren

Hydrocephalus is a common problem in Neurosurgery and Neurology. The usual treatment is the installation of a Ventricular Peritoneal Shunt (VPS). Infection is the most frequent and serious complication. With the aim to identify risk factors associated with infection in the post surgery of VPS in pediatric patients from Carlos Van Buren Hospital a case control study between 1998-2008 was done. Cases were patients with VPS infection reported to the Department of Nosocomial Infections. Results in contingency tables were analyzed to determine Odds Ratio. 264 surgical procedures were studied in 207 patients with 53 infections reported in 26 patients. Significant risk factors were: history of prior ventriculitis, VPS dysfunction and prior external ventricular shunt, concurrent infections at the time of surgery and a neurosurgeon without the specialty of pediatric neurosurgery. We concluded that antibiotic prophylaxis was not an important factor in preventing infection and the neurosurgeon experience is relevant to the development of VPS infections.

La hidrocefalia es un problema común en neurocirugía y neurología. Su tratamiento habitual es la instalación de una válvula derivativa ventrículo peritoneal (DVP) cuya complicación más grave y frecuente es la infección. Con el propósito de identificar los factores de riesgo de infección post-operatoria en pacientes con DVP del Hospital Carlos Van Buren (HCVB), se realizó un estudio caso-control en la población pediátrica con DVP instalada entre 1998 y 2008. Los casos fueron pacientes con una infección de DVP notificada en el Departamento de Infecciones Intrahospitalarias (IIH), y controles los que no presentaron infección. Se analizaron los resultados en tablas de contingencia para determinar los Odds Ratio correspondientes. Se estudiaron 264 procedimientos quirúrgicos, 207 pacientes y 53 infecciones notificadas en 26 enfermos. Los factores de riesgo significativos fueron el antecedente de ventriculitis previa, disfunción de DVP previa, derivativa ventricular externa previas, infecciones concomitantes al momento de la cirugía, y que el neurocirujano no tuviera la especialidad en neurocirugía pediátrica. Se concluyó que la profilaxis antimicrobiana no fue un factor importante en la prevención de infecciones y que la experiencia del neurocirujano es relevante en el desarrollo de infecciones de DVP.

[23-valent pneumococcal vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010]. / Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología acerca de la eficacia de la vacuna anti-neumocóccica 23 valente en el adulto mayor: Febrero 2010.

The article summarizes the scientific evidence related with protection conferred by the 23 valent polysaccharide vaccine against invasive pneumococcal disease, non bacteraemic pneumococcal pneumonia, and probable pneumococcal pneumonia in the elderly. Eider patients with and without risk factors are considered. The impact of herd immunity conferred by vaccination of children with conjugated pneumococcal vaccine in reduction of pneumonia in adults is discussed. Based on this analysis, the Advisory Committee on Immunizations of the Chilean Infectious Disease Society makes recommendations on the most efficient vaccine strategy for reduction of pneumococcal pneumonia in the elderly.

Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología acerca de la eficacia de la vacuna anti-neumocóccica 23 valente en el adulto mayor: Febrero 2010 / 23-Valent Pneumococcal Vaccine: Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010

The article summarizes the scientific evidence related with protection conferred by the 23 valent polysacchar-die vaccine against invasive pneumococcal disease, non bacteriemic pneumococcal pneumonia, and probable pneumococal pneumonia in the elderly. Eider patients with and without risk factors are considered. The impact of herd immunitty conferred by vaccination of children with conjugated pneumococcal vaccine in reduction of penumonia in adults is discussed. Based on this analysis, the Advisory Committee on Immunizations of the Chilean Infectious Disease Society makes recommendations on the most efficient vaccine strategy for reduction of pneumococcal pneumonia in the elderly.

El artículo resume los hallazgos de la evidencia científica en relación a la protección que confiere la vacuna neumocóccica polisacárida 23 valente contra la enfermedad neumocóccica invasora, las neumonías neumocóccicas no bacteriémicas y las neumonías probablemente de etiología neumocóccica en el adulto mayor, estableciendo una categorización entre adultos mayores con factores de riesgo y sin ellos. Se documenta a la vez, el impacto que ha tenido la vacuna neumocóccica conjugada en la población infantil, en reducir las neumonías en el adulto mayor. Basados en la información disponible, el Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología, realiza recomendaciones sobre cuál sería la mejor forma de prevenir las enfermedades neumocóccicas en el adulto mayor.

Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología respecto a la vacuna anti-virus papiloma humano: septiembre 2008 / Human papillomavirus vaccine: statement of the Consultive Committee of Immunizations on behalf of The Chilean Infectious Diseases Society: September 2008

The article briefly reviews the epidemiology of human papillomavirus (HPV) infection and associated diseases in the world and in Chile and the scientific information of the licensed HPV vaccines: Gardasil® and Cervarix®. Considering the available information, the Consultive Committee of Immunizations of the Chilean Society of Infectious Diseases, summarizes its conclusions and makes recommendations for vaccination against HPV in Chile.

El artículo revisa brevemente la epidemiología de las infecciones por virus papiloma humano (VPH) y las enfermedades asociadas, tanto en el mundo como en Chile y la información científica de las vacunas contra VPH licenciadas: Gardasil® y Cervarix®. Considerando la información disponible, el Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología, resume sus conclusiones y hace sus recomendaciones para la vacunación contra VPH en Chile.

Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología respecto a la vacuna antivirus papiloma humano: Septiembre 2008 / Human papillomavirus vaccine: Statement of the Advisory Committee of Immunizations on Behalf of the Chilean Infectious Diseases Society: September 2008

This article briefly reviews the epidemiology of human papillomavirus (HPV) infection and associated diseases globally and in Chile, and the scientific ínformatíon of the licensed HPV vaccines: Gardasil® and Cervarix®. Considering the available information, the Advisory Committee on Immunizations of the Chilean Society of Infectious Diseases recommends vaccination of teenage girls, ideally before initiating sexual actívíty, Le. approximately at the age of 12 to 13 years and vaccination of women of any age if they have not started sexual activity. If women are vaccinated after initiating sexual activity, they should be informed of the lower efficacy of immunization if HPV infection has occurred. Education on responsible sexuality and sexually transmitted diseases should be maintained as a priority. Vaccination should be highly considered for inclusion in the National Immunization Program.

[Invasive pneumococcal disease and consolidated pneumonia in infants: one year of surveillance in three Chilean health care centers]. / Infección neumocóccica invasora y neumonía consolidante en lactantes: Un año de vigilancia en tres centros hospitalarios chilenos.

OBJECTIVE: To describe frequency and type of invasive pneumococcal diseases (IPD) and consolidated pneumonia (CP) in Chilean infants. PATIENTS AND METHODS: One-year prospective surveillance in three health care centers. PID surveillance: blood culture in infants with suspected invasive bacterial disease or with fever higher than 39 degrees C axillary without focus or with acute otitis media. CP surveillance: blood culture and independent evaluation of chest X-ray in infants with suspected pneumonia. RESULTS: IPD: in 4,369 infants studied, 58 cases of invasive bacterial diseases were identified, 37 (64%) due to S. pneumoniae. Rates of IPD: 110/100,000 (Chilian) and 288/100,000 (Valparaiso). Serotypes identified: 18C(n: 8), 14 (n: 8), 19A(n: 5), others (n: 12). CP: in 3,005 infants 762 CP were detected. Rates of CP: 2,918/100,000 (Chilian) and 5,547/100,000 (Valparaiso). DISCUSSION: Results support the relevance of S. pneumoniae as the main cause of invasive bacterial disease and the high frequency of CP in this age group in Chile.

Infección neumocóccica invasora y neumonía consolidante en lactantes: Un año de vigilancia en tres centros hospitalarios chilenos / Invasive pneumococcal disease and consolidated pneumonia in infants: One year of surveillance in three Chilean health care centers

Objetivo: Describir la frecuencia y tipo de enfermedad neumocóccica invasora (ENI) y neumonía consolidante (NC) en lactantes chilenos. Pacientes y Métodos: Vigilancia prospectiva durante un año en tres centros. Vigilancia de ENI: hemocultivo en lactantes con sospecha clínica de enfermedad bacteriana invasora (EBI) o fiebre > 39 °C axilar, sin foco o con otitis media aguda. Vigilancia de NC: hemocultivo y evaluación independiente de la radiografía en lactantes con sospecha clínica de neumonía. Resultados: ENI: en 4.369 lactantes enrolados se detectaron 58 casos de EBI, 37 (64 por ciento) por Streptococcus pneumoniae. Tasas de ENI: 110/100.000 (Chillan) y 288/100.000 (Valparaíso). Serotipos de S. pneumoniae identificados: 18C (n: 8), 14 (n: 8), 19A (n: 5), otros (n: 12). NC: en 3.005 niños enrolados se detectaron 762 NC. Tasas de NC: 2.918/ 100.000 (Chillan) y 5.547/100.000 (Valparaíso). Discusión: Se confirma la relevancia de S. pneumoniae como agente de EBI así como la elevada frecuencia de NC en lactantes en Chile.

Objective: To describe frequency and type of invasive pneumococcal diseases (IPD) and consolidated pneumonia (CP) in Chilean infants. Patients and Methods: One-year prospective surveillance in three health care centers. PID surveillance: blood culture in infants with suspected invasive bacterial disease or with fever higher than 39°C axillary without focus or with acute otitis media. CP surveillance: blood culture and independent evaluation of chest X-ray in infants with suspected pneumonia. Results: IPD: in 4,369 infants studied, 58 cases of invasive bacterial diseases were identified, 37 (64 percent) due to S. pneumoniae. Rates of IPD: 110/100,000 (Chilian) and 288/100,000 (Valparaiso). Serotypes identified: 18C(n: 8), 14 (n: 8), 19A(n: 5), others (n: 12). CP: in 3,005 infants 762 CP were detected. Rates of CP: 2,918/100,000 (Chilian) and 5,547/100,000 (Valparaiso). Discussion: Results support the relevance of S. pneumoniae as the main cause of invasive bacterial disease and the high frequency of CP in this age group in Chile.

[Human papillomavirus vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society. September 2008]. / Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología respecto a la vacuna anti-virus papiloma humano. Septiembre 2008.

The article briefly reviews the epidemiology of human papillomavirus (HPV) infection and associated diseases in the world and in Chile and the scientific information of the licensed HPV vaccines: Gardasil and Cervarix. Considering the available information, the Consultive Committee of Immunizations of the Chilean Society of Infectious Diseases, summarizes its conclusions and makes recommendations for vaccination against HPV in Chile.

[Safety of thimerosal containing vaccines. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society]. / Seguridad de las vacunas que contienen timerosal: Declaración del Comité Consultivo de Inmunizaciones (CCI) de la Sociedad Chilena de Infectología.

Thimerosal is a mercury derivative included in vaccines since 1930 with the aim to prevent microbial contamination. During the last decades, the use of thimerosal has been questioned, specifically because of a potential association with neurotoxicity. After a thorough review of published studies on pediatric use of thimerosal-containing vaccines, and of position papers from international expert groups, the Consultive Committee of Immunizations of the Chilean Society of Infectious Diseases concludes that there is no solid evidence of adverse events associated with the use of thimerosal containing vaccines in infants and children. Therefore, a change in current vaccine practices refererred to thimerosal-containing vaccines is not justified in Chile.

[Incidence of severe rotavirus gastroenteritis among Chilean children under three years of age]. / Impacto de gastroenteritis severa por rotavirus en niños chilenos menores de 3 años de edad.

BACKGROUND: Rotavirus infections account every year in Chile, for approximately 53,000 emergency consultations and 8,000 hospital admissions among children under three years of age. AIM: To estimate incidence rates of severe rotavirus gastroenteritis in children <3 years of age, living in the V and VIII Regions and to identify the predominant viral serotypes. MATERIAL AND METHODS: A prospective hospital-based surveillance for severe gastroenteritis was implemented in public and private hospitals of Viña del Mar and Valparaiso (Region V) and of Chiguayante, Concepción, Penco, San Pedro de la Paz, Talcahuano and Tomé (Region VIII). All children <3 years of age residing in the districts, who consulted for severe gastroenteritis requiring oral or intravenous rehydration (equivalent to WHO plan B or C), or who were admitted to the hospital, were enrolled. Demographic and clinical information and a stool sample were obtained. Rotavirus was detected by ELISA and positive samples were serotyped by ELISA or real time PCR. RESULTS: Between January 23 and June 30, 2003, a total of 760 children were recruited. Among these, 343 (45%) were admitted to the hospital. Stool samples were collected from 433 children. Among these, 214 were positive for rotavirus (49.4%). Overall, monthly disease incidence rates were 124/100,000 in V Region, and 114/100,000 in VIII Region. The predominant serotype was G4. CONCLUSIONS: Rotavirus was responsible for nearly half of the severe gastroenteritis episodes among children <3 years, during a predominantly G4 serotype season. Every year, approximately one every 70 children <3 years will have a severe rotavirus gastroenteritis episode.

Seguridad de las vacunas que contienen timerosal: Declaración del Comité Consultivo de Inmunizaciones (CCI) de la Sociedad Chilena de Infectología / Safety of thimerosal containing vaccines. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society

El timerosal es un derivado del mercurio utilizado desde 1930 como preservante de vacunas. En las últimas décadas ha sido cuestionada su seguridad, especialmente por la posibilidad de toxicidad neurológica. La revisión de varios estudios realizados en niños que recibieron vacunas que contienen timerosal y la posición de organismos de expertos internacionales en relación al uso de este compuesto en vacunas, permite al Comité Consultivo de Inmunizaciones concluir que no existe evidencia de eventos adversos en lactantes o niños por exposición al timerosal contenido en vacunas rutinarias y, por lo tanto, no habría razón para modificar las actuales prácticas de inmunización en Chile.

Thimerosal is a mercury derivative included in vaccines since 1930 with the aim to prevent microbial contamination. During the last decades, the use of thimerosal has been questioned, specifically because of a potential association with neurotoxicity. After a thorough review of published studies on pediatric use of thimerosal-containing vaccines, and of position papers from international expert groups, the Consultive Committee of Immunizations of the Chilean Society of Infectious Diseases concludes that there is no solid evidence of adverse events associated with the use of thimerosal containing vaccines in infants and children. Therefore, a change in current vaccine practices refererred to thimerosal-containing vaccines is not justified in Chile.

Impacto de gastroenteritis severa por rotavirus en niños chilenos menores de 3 años de edad / Incidence of severe rotavirus gastroenteritis among Chilean children under three years of age

Background: Rotavirus infections account every year in Chile, for approximately 53,000 emergency consultations and 8,000hospital admissions among children under three years of age. Aim: To estimate incidence rates of severe rotavirus gastroenteritis in children <3 years of age, living in the V and VIII Regions and to identify the predominant viral serotypes. Material and methods: A prospective hospital-based surveillance for severe gastroenteritis was implemented in public and private hospitals of Viña del Mar and Valparaiso (Region V) and of Chiguayante, Concepción, Penco, San Pedro de la Paz, Talcahuano and Tomé (Region VIII). All children <3 years of age residing in the districts, who consulted for severe gastroenteritis requiring oral or intravenous rehydration (equivalent to WHO plan B or C), or who were admitted to the hospital, were enrolled. Demographic and clinical information and a stool sample were obtained. Rotavirus was detected by ELISA and positive samples were serotyped by ELISA or real time PCR. Results: Between January 23 and June 30, 2003, a total of 760 children were recruited. Among these, 343 (45 percent) were admitted to the hospital. Stool samples were collected from 433 children. Among these, 214 were positive for rotavirus (49.4 percent). Overall, monthly disease incidence rates were 124/100,000 in V Region, and 114/100,000 in VIIIRegion. The predominant serotype was G4. Conclusions: Rotavirus was responsible for nearly half of the severe gastroenteritis episodes among children <3 years, during a predominantly G4 serotype season. Every year, approximately one every 70 children <3 years will have a severe rotavirus gastroenteritis episode.

Detección de enterovirus mediante transcripción reversa y reacción de polimerasa en cadena en líquido cafalorraquídeo de niños con meningitis aséptica / Detection of enterovirus by reverse transcriptase and polymerase chain reaction in cerebrospinal fluid samples of children with aseptic meningitis

Los enterovirus causan cerca de 90 por ciento de las meningitis asépticas (MA). La ausencia de un buen método de diagnótico etiológico determina con frecuencia tratamientos innecesarios. En este estudio se comparó la detección de enterovirus en líquido cefalorraquídeo (LCR) usando cultivos celulares e inmunofluorescencia indirecta (CC/IFI), con la reacción de polimerasa en cadena (RT-PCR). Se estudiaron 22 muestras de LCR provenientes de niños con MA (casos) y 17 de niños con otras patologías (controles). Todos fueron atendidos en servicios pediátricos del Hospital Carlos Van Buren de Valparaiso. Hubo 100 por ciento de concordancia entre ambos métodos en los 22 niños con MA, encontrándose 21 casos positivos para enterovirus. Entre los 17 controles, 2 muestras resultaron por RT-PCR y una de ellas lo fue también por CC-IFI. La RT-PCR resultó un método sencible y específico. Considerando la rapidez con que se puede tener los resultados es esperable que su uso rutinario sea beneficioso para los pacientes con MA

Antrax / Anthrax

Agente: Bacillus anthracis. (Bacilo Gram positivo, aerobio estricto, esporulado, inmóvil). Reservorio: Herbívoros y sus subproductos, ambiente contaminado con esporas. Transmisión: Pasto con esporas ingestión por ganado esporas en carne, subproductos o suelo humano: contacto con piel, epitelio respiratorio, bucofaríngeo o intestinal. Laboratorio: Gram y cultivo en agar sangre de tejidos o líquidos infectados. Prevención: Vacuna y antimicrobianos Tratamiento: Penicilina V oral o g endovenosa, por un plazo variable de al menos 7 a 10 días. Alternativas: eritromicina, cloranfenicol, tetraciclina y ciprofloxacina